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The antibacterial activity of polyoxometalates:
structures, antibiotic eﬀects and future
perspectives†
Aleksandar Bijelic, a Manuel Aureliano b and Annette Rompel *a
Polyoxometalates (POMs) are, mostly anionic, metal oxide compounds that span a wide range of tunable
physical and chemical features rendering them very interesting for biological purposes, an continuously
emerging but little explored field. Due to their biological and biochemical eﬀects, including antitumor,
-viral and -bacterial properties, POMs and POM-based systems are considered as promising future
metallodrugs. In this article, we focus on the antibacterial activity of POMs and their therapeutic
potential in the battle against bacteria and their increasing resistance against pharmaceuticals. Recent
advances in the synthesis of POMs are highlighted, with emphasis on the development and properties of
biologically active POM-based hybrid and nanocomposite structures. By analysing the antibacterial
activity and structure of POMs, putative mode of actions are provided, including potential targets for
POM–protein interactions, and a structure–activity-relationship was established for a series of POMs
against two bacteria, namely Helicobacter pylori and Streptococcus pneumoniae.
1. Introduction
Polyoxometalates (POMs) are a class of discrete, mostly anionic,
clusters of early transition metal oxides (mostly Mo-, W- and
V-oxides) exhibiting a broad diversity of structures and out-
standing properties.1 There are twomajor types of POMs, namely
isopoly- and heteropolyoxoanions with the general formulas
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[MmOy]
n and [XxMmOy]
n, respectively, where M represents the
addenda atom, which is mostly restricted to W, Mo and V, and
X the central heteroatom, which can be almost any other
element. A myriad of POM structures have been synthesized
in the last decades and their broad variety of physicochemical
properties led to their application in various fields such as
catalysis,2 photochemistry,3 electrochemistry,4 material science,5
protein crystallography6,7 and medicine.8 Biological applications
of POMs are very promising as almost every feature that aﬀects
the interaction of POMs with biological target macromolecules
can be altered in order to enhance their beneficial activities on
the respective biological system.6,9 With targeted and reprodu-
cible synthetic routes, it is nowadays possible to obtain tailor-
made POM systems, including organic–inorganic hybrids and
other nanocomposites, with enhanced biological properties.10–17
The foundation for the research of biologically active POMs has
been laid in 1970, when Chermann et al. discovered the inhibi-
tory effect of silicotungstic acid on murine leukaemia and
sarcoma viruses.18 This led to systematic studies of the antiviral
effect of this and other POMs revealing that enzyme inhibition
(e.g. inactivation of reverse transcriptase in the case of HIV)
plays a major role for their activity.19–21 Further biological
activities were consequently discovered: the insulin mimetic
effect of POMs to combat diabetes;22–25 anticancer23,26,27 and
antibiotic23,27,28 activities, and the antiparasitic potential of
decavanadate against leishmania.29 It is believed that in many
cases these POM-associated biological activities are the result of
POM–protein/POM–enzyme interactions, which are of electro-
static nature as evidenced by crystallographic studies showing
that the negatively charged metal clusters are mainly found
within or at positively charged regions of the proteins.6,30–36
However, also covalent interactions between biomacromole-
cules and POMs are possible as was shown by our group.35
The inhibition of certain enzymes by POMs can trigger the
impairment of vital cell functions.37 In this regard, the group of
Aureliano extensively studied the interaction between POMs,
especially polyoxovanadates (POVs), and diverse biochemical
targets like ion pumps.6,38–40 However, the exact mode of the
biological activity of POMs is still elusive and thus also the POM’s
target biomolecules, which are responsible for the observed
biological effects. This article focuses on antibacterially active
POMs as bacteria pose a threat to global public health, especially
due to the rapid emergence of resistant bacteria occurring world-
wide. Besides the activity of purely inorganic POMs, the anti-
microbial potentials of POM-based hybrid and nanocomposite
structures represent highlights of this article emphasizing the
recent developments in the synthetic approach of POMs. Using
our experience regarding POM–protein interactions, we tried to
deduce structure–activity-relationships and potential targets to
provide possible mode of actions for the antibacterial activity
of POMs.
2. Antibacterial activity of
inorganic POMs
The antibacterial activity of purely inorganic POMs can be
subdivided into two major modes, namely (1) synergistic and
(2) direct antibacterial activity. Most of the inorganic POMs did
not exhibit significant antibacterial activity at pharmacologi-
cally acceptable concentrations but were active in synergy with
conventional antibiotics.
2.1. Synergistic activity of inorganic POMs
As is often the case with discoveries, it was serendipity that the
group of Tajima revealed the antibacterial properties of POMs in
1993.28 Back then, they reported on an aged mixture of tungstate
and phosphate named ‘Factor T’, which greatly enhanced the
antibacterial eﬀect of b-lactam antibiotics in methicillin-resistant
Staphylococcus aureus (MRSA) strains, which is a Gram-positive
bacteria and one of the most resistant ones around the
world. Years later, namely in 1997, ‘Factor T’ was identified as
the lacunary Keggin POM species [PW11O39]
7 (Fig. 1F).41
[PW11O39]
7 showed only synergistic eﬀects with b-lactam-
based antibiotics and was only active on MRSA, Staphylococcus
epidermis and Staphylococcus auricularis. Inspired by these
findings, the same group investigated the antibacterial activity of
b-lactam antibiotics in synergy with in total 76 POMs (Tables S1
and S2, ESI†).42–46 Fig. 1 illustrates the most prominent POM
structures that were used for these antibacterial studies. The
results revealed that especially Keggin- (including lacunary,
double and sandwich structures) and Wells–Dawson-type
(including lacunary structures) structures were most potent in
terms of sensitizing the MRSA strains SR3605 (constitutive
resistance) and ATCC43300 (inducible resistance) towards
b-lactam antibiotics. While almost all investigated polyoxotung-
states (POTs) showed promising synergistic activity by exhibit-
ing an average fractional inhibitory concentration (FIC) index of
o0.5 (average FICPOTs B 0.141), the tested polyoxomolybdates
(POMos) and polyoxovanadates (POVs) did not exhibit any
significant effect with the b-lactam antibiotic on neither MRSA
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strain (average FICPOMos B 0.725 and FICPOVs B 0.740).
42–45
Some POMs like the Wells–Dawson-type [P2W18O62]
6 (Fig. 1D)
and the Keggin-type [SiMo12O40]
4 (Fig. 1C) exhibited sensitizing
effects also against vancomycin-resistant Staphylococcus aureus
(VRSA) strains, which is surprising for the latter POM as POMos
were in general ineffective against MRSA.42,43 Some lacunary
Keggin structures (Fig. 1F and G), especially tungstates, were
more effective than their fully saturated parent structure sug-
gesting a special role for the lacuna.44,45 For example, the FIC of
[SiW12O40]
4 against the MRSA strain SR3605 is 0.094, whereas
the value for the corresponding lacunary structure [SiW11O39]
8
is 0.041. However, a series of lacunary-substituted [SiW11O39]
8
structures, where the lacuna was filled by VIVO, CrIII, MnII,
FeII/III, CoII, NiII, CuII, LaIII, YbIII or BiIII, had very similar or even
stronger sensitizing effects than the unsubstituted species
(e.g. FIC against MRS394-1 of [SiW11O39]
8 = 0.041 vs. FIC of
[SiW11O39Co(II)]
6 = 0.033) indicating that the hole in the
lacunary structure has no activity-enhancing effect.44,45 Further-
more, there was no obvious correlation between the activity and
the substituted metal.
It is known that the b-lactam resistance of bacteria is
acquired by the expression of a peptidoglycan-synthetic enzyme
that possesses a low aﬃnity for b-lactam, namely the penicillin-
binding-protein 2a (PBP2a), which is encoded by the mecA
gene.47 Yamase group demonstrated that POTs ([P2W18O62]
6
and [PTi2W10O40]
7) aﬀect the transcription process of PBP2a
in MRSA.42,43,48 Suppression of PBP2a formation inhibits the
resistance mechanism of MRSA and increases its susceptibility
towards b-lactam antibiotics, which then interfere with the cell
wall generation. POTs were also shown to reduce the produc-
tion of b-lactamase, an antibiotic resistance-associated enzyme,
which inactivates b-lactam antibiotics by hydrolyzing their
b-lactam ring.43 Thus, POTs are able to overcome two kinds
of bacterial resistance modes against b-lactam antibiotics.
Fig. 1 Overview of most prominent and commonly used POM structures. (A) Lindqvist, (B) Anderson-Evans, (C) Keggin, (D) Wells–Dawson,
(E) decavanadate, (F) monolacunary Keggin, (G) trilacunary Keggin, (H) Keggin sandwich and (I) double Keggin structure are shown in polyhedra
representation mode. X = heteroatom (ochre polyhedra), M = addenda atom (cyan polyhedra) and Y = other metal (dark blue octahedra and yellow ball,
respectively). The scheme within the figure illustrates how the mono- and trilacunary Keggin structures are deduced from the fully saturated parent
Keggin structure by subtracting one and three MO6 octahedra, respectively, and the origin of the two large Keggin-structures (H) and (I). Vanadium atoms
are shown as grey octahedra, whereas oxygen atoms are illustrated as small red spheres.
ChemComm Feature Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
Ja
nu
ar
y 
20
18
. D
ow
nl
oa
de
d 
on
 2
2/
01
/2
01
8 
18
:1
3:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Chem. Commun. This journal is©The Royal Society of Chemistry 2018
The biological reduction of POMs, more precisely [P2W18O62]
6,
in MRSA and VRSA cells was observed by dispersive X-ray analysis
and transmission electron microscopy revealing the accumulation
of POMs at the periphery of the bacterial cells.48
2.2. Direct antibiotic activity of inorganic POMs
2.2.1. Direct antibiotic activity against Gram-positive bacteria.
Only a few POMs (Tables S1 and S2, ESI†), which were tested
against diﬀerent Staphylococcus aureus strains, showed significant
antibacterial activity on their own accord by exhibiting aminimum
inhibitory concentration (MIC) of o100 mg ml1 (for comparison
good antibiotic drugs have MIC values ranging from 0.001 to
10 mg ml1). These POMs were [Ge2Ti6W18O77]
14 43 (Fig. 1I)
(MIC = 50 mg ml1 vs. SR3605, 10–25 mg ml1 vs. ATCC43300),
[V10O28]
6 49 (Fig. 1E) (MIC = 50 mg ml1 vs. SR3605) and
[Si2Nb6W18O77]
8 43 (Fig. 1I) (MIC = 25 mg ml1 vs. ATC43300).
Fukuda and Yamase tested the antibacterial activity of 20 purely
inorganic POMs against six strains of Streptococcus pneumoniae
(penicillin-intermediate-resistant IID553, IID554 and penicillin-
resistant BS225, BS234, BS259, BS269) without the use of any
additional antibiotic (Table S3, ESI†).50 All tested POVs showed
high antibacterial activities with MIC values in the range
of 4–32 mg ml1 (positive control with conventional antibiotics:
2–32 mg ml1), whereas the used POTs and POMos were signi-
ficantly less active with MIC values ofB128–8000 mg ml1. Two
of the investigated POVs, [V4O12]
4 and [MnV13O38]
7, were
subsequently tested against various other bacteria (MRSA,
methicillin-susceptible Staphylococcus aureus, coagulase-negative
staphylococci, Enterococcus faecalis, E. coli and Pseudomonas
aeruginosa) and did not show any significant inhibitory activity
at the investigated concentrations indicating that these POVs
are selectively active against Streptococcus pneumoniae. The
study also revealed that POVs, more precisely [V4O12]
4 and
[V10O28]
6, did not only inhibit the incorporation of the sub-
strates thymidine, uridine, leucine and glucose into the cell in a
non-selective manner but also induced potassium efflux from
the cells indicating that the inhibitory activity of POVs against
Streptococcus pneumoniae is partially based on their interference
with the transport of substrates and ions.50
The group of Aureliano extensively investigated the eﬀects
of POVs on biologically relevant macromolecules such as ion
pumps and therefore it is suggested that the interaction of
certain POVs such as decavanadate [V10O28]
6 with, for example,
P-type ATPases may induce the uncoupling of ATP hydrolysis
and thus transforming these ion pumps into channels, which
under certain circumstances can severely aﬀect cellular ion
gradients and concomitantly lead to the death of the
organism.40,51 This kind of ATPase inhibition was, among other
inhibition mechanisms, also suggested for palytoxin, a marine
toxin, which induces K+ eﬄux upon exposition to Na+/K+-ATPase
by putatively uncoupling the ion pump and inducing the for-
mation of channels.40,52–54 Decavanadate was also observed to
mediate cell distortions that led to concentration-depending
morphological changes of the bacterial cells.50 Elongated bac-
teria cells were observed at POV concentration less than MIC,
whereas at a high concentration (100 mg ml1) the cells became
swollen indicating cell death (bactericidal activity). Morphol-
ogical changes can be ascribed, at least partially, to changes in
cytoskeletal dynamics.55 Considering this, [V10O28]
6 was also
reported to affect the G-actin polymerization in animals39 as
POVs are able to interact with actin at its ATP binding site,56
which might also explain some POV-mediated effects in bacteria
as their cytoskeleton possesses homologous elements to actin
that control the bacterial shape such as MreB.57 MreB is present
in both Gram-positive and -negative bacteria and is involved in
relevant cellular functions such as coordination of cell wall
formation and chromosome segregation and therefore repre-
sents a promising target.58
2.2.2. Direct antibiotic activity against Gram-negative bacteria.
As late as 2005, the first study devoted to the antibacterial
activity of POMs against a Gram-negative bacterium was pub-
lished (Gram-negative bacteria possess a thinner peptidoglycan
layer in comparison to Gram-positive ones but instead contain
an additional membrane, namely the outer membrane).46
Yamase group tested 13 POMs on Helicobacter pylori (Table 3),
which is usually found in the stomach and responsible for the
majority of ulcers in the stomach and small intestine. Regard-
ing the antibacterial eﬀect of POMs, highly negatively charged
POTs such as [KAs4W40O140]
27, [KSb9W21O86]
18, Keggin-type
POTs and polyoxovanadotungstates (Fig. 1) have shown promising
antibacterial activity on their own accord (MICso 100 mg ml1).46
The former large cryptate anion, [KAs4W40O140]
27, exhibited
the highest activity and was even more active than the antibiotic
drug metronidazole (MTZ) against MTZ-susceptible Helicobacter
pylori strains when comparing the MIC values in mM units
(MICPOT B 1.4 mM vs. MICMTZ B 2.9–23.4 mM). However, none of
the most active POTs, [KAs4W40O140]
27 (MIC = 1.4 mM/16 mg ml1),
[KSb9W21O86]
18 (MIC = 2.3–9.0 mM/16–64 mg ml1) and
[SiVW11O40]
5 (MIC = 5.4–87.2 mM/16–256 mg ml1), exhibited
synergistic effects with the antibiotics MTZ, amoxicillin and
clarithromycin as indicated by FIC indices of 40.5. Further-
more, it was shown that the investigated POTs are uptaken into
the cells of the Gram-negative bacterium, more precisely, into
the periplasmic space or the inner membrane but not into the
cytoplasm, which was also shown for Gram-positive bacteria.
The authors suggested that POM incorporation into Gram-
negative cells is mediated by porins.46 As was already the case
for Gram-positive bacteria like MRSA, POMos exhibited only
minor activity against the Gram-negative Helicobacter pylori
(MIC values of4256 mg ml1/140–236 mM) which is most likely
due to the lower chemical stability of molybdate in comparison
to tungstate, demonstrating the importance of the stability of
POMs for their biological activity.
Another example of directly exhibited antibacterial activity
of POMs is the photocatalytic inactivation of Escherichia coli
(Gram-negative) and Bacillus subtilis (Gram-positive) by the Keggin
heteropolyacids H3PW12O40, H3PMo12O40 and H4SiW12O40.
59
The investigated POMs showed also some antibacterial activity
in the absence of UV-irradiation but to a much lesser extent
than upon UV-excitation. The POM-mediated photocatalytic
inactivation performances were superior to that of TiO2, which
is a known photocatalytic disinfectant. The concentration of
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inactivated cells (e.g. Escherichia coli), after 20 minutes of
UV-irradiation, was three orders of magnitude higher in the
presence of 0.05 mM H3PMo12O40 or 0.1 mM H4SiW12O40 than
in the presence of 12.5 mM of the control TiO2, whereas in the
presence of 0.35 mM H3PW12O40 it was only one order of
magnitude higher. The antibacterial activity was ascribed to
the oxidant power of the excited POMs as they were able to carry
out the in situ alcohol dehydrogenation of methanol demon-
strating their ability to exhibit damaging oxidation reactions
within the cell, which, finally, could lead to cell death.
Table 1 summarizes the eﬀects of the above described inorganic
POM-types on all tested bacteria.
3. Antibacterial activity of POM-based
organic–inorganic hybrids
A major focus in the field of POMs lies on the synthesis of
organic–inorganic hybrid structures, that is, the attachment of
organic moieties to the POM core. This expands the already rich
structural and functional versatility of POMs and opens the
door to further applications.10,13,16 Organic functionalities are
especially interesting for bioactive POMs as they do not only
enhance the stability of the POMs in certain media but also
their interaction with biologically important targets. In this
way, the antibacterial properties of some POMs were drastically
improved.
3.1. Organoantimony(III)-containing POTs
The groups around Kortz and Ullrich synthesized a series of
organoantimony(III)-containing POTs and tested their anti-
bacterial activity on a variety of bacterial strains. The first three
reported organic–inorganic POM hybrids of this series were
[(PhSbIII)4(A-a-Ge
IVW9O34)2]
12, [(PhSbIII)4(A-a-P
VW9O34)2]
10
and [{2-(Me2NCH2C6H4)Sb
III}3(B-a-As
IIIW9O33)]
3 (Ph = phenyl
group, Me = methyl group).61 All three hybrid POTs were
stable in aqueous media at physiological pH and showed
promising antibacterial activity against both Escherichia coli
Table 1 Overview of the eﬀect of purely inorganic POMs on all tested bacteria
POM-type
Synergistic
eﬀect ona Ref.
No synergistic
eﬀect ona Ref.
Antibacterially active
on (alone) Ref.
Antibacterially
inactive
on (alone) Ref.
Polyoxotungstates: MR/VR S. aureus(+) 42–46 MR S. haemolyticus(+) 45 and 60 S. pneumoniae(+) 50 MR/VR S. aureus(+) 42–46
MR S. epidermis(+) 60 MR S. capitis(+) 45 and 60 (very low activity) MR S. epidermis(+) 43 and 60
MR S. auricularis(+) 60 MR S. caprae(+) 45 and 60 B. subtilis(+)b 59 MR S. auricularis(+) 60
MS S. haemolyticus(+) 60 MR S. saprolyticus(+) 45 and 60 DS H. pylori()c 46 MS S. haemolyticus(+) 45 and 60
MZR H. pylori() 46 MR S. sciuri(+) 45 and 60 MZR H. pylori()c 46 MR S. haemolyticus(+) 45 and 60
CLR H. pylori() 46 PR S. pneumoniae(+) 50 CLR H. pylori()c 46 MR S. capitis(+) 60
PR E. faecalis(+) 60 E. coli()b 59 MR S. caprae(+) 60
PR E. coli() 60 MR S. saprolyticus(+) 60
PR E. cloacae() 60 MR S. sciuri(+) 60
PR P. aeruginosa() 60 PR S. pneumoniae(+) 60
BLR S. marcescens() 60 PR E. faecalis(+) 60
CPR K. pneumoniae() 60 PR E. coli() 60
PR E. cloacae() 60
PR P. aeruginosa() 60
BLR S. marcescens() 60
CPR K. pneumoniae() 60
Polyoxomolybdates: MR/VR S. aureus(+)
(only [SiMo12O40]
4)
42–46 MR/VR S. aureus(+)
(except [SiMo12O40]
4)
42–46 S. pneumoniae(+)
(very low activity)
50 MR/VR S. aureus(+) 42–46
DS H. pylori()
(very low activity)
46
MZR H. pylori()
(very low activity)
46
CLR H. pylori()
(very low activity)
46
Polyoxovanadates: MR/VR S. aureus(+) 42, 43
and 50
MR/VR S. aureus(+) 42–46 PR S. pneumoniae(+) 50 MR/VR S. aureus(+)
(except [V10O28]
6)
42, 43
and 50
MR S. aureus(+)
(only [V10O28]
6)
49 CoN Staphylococci(+) 50
PR E. faecalis(+) 50
E. coli() 50
P. aeruginosa() 60
a POM used in combination with an antibiotic drug (b-lactam antibiotics). b Antibacterial activity of POTs against E. coli and B. subtilis via
photocatalytic inactivation (see text). c Only Keggin and huge and highly charged POTs ([KAs4W40O140]
27 and [KSb9W21O86]
18, see text) were
antibacterially active against H. pylori strains. (+)/() indicate Gram-positive and -negative bacteria, respectively. MR = methicillin resistant,
VR = vancomycin-resistant, MZR = metronidazole-resistant, CLR = clarithromycin-resistant, PR = penicillin-resistant, BLR = b-lactam-resistant
(in general), CPR = carbapenem-resistant, DS = drug-susceptible, CoN = coagulase negative. Note that for bacteria lacking a resistance label there
was either no further information in the respective publication or a normal drug-susceptible bacterium was used. For more information regarding
the exact POM-type, please see Table 3 and Tables S1–S4 (ESI).
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and Bacillus subtilis (MIC values ranging from 40–130 mg ml1)
with the latter Gram-positive bacterium being slightly more sensi-
tive to the POTs. [{2-(Me2NCH2C6H4)Sb
III}3(B-a-As
IIIW9O33)]
3
(MIC = 130 mg ml1 against E. coli and 60 mg ml1 against
B. subtilis) was slightly less active than the other two com-
pounds, whereas [(PhSbIII)4(A-a-Ge
IVW9O34)2]
12 (MIC = 80 and
40–80 mg ml1) was more active than [(PhSbIII)4(A-a-P
VW9O34)2]
10
(MIC = 110 and 50 mg ml1) indicating the importance of both
the structure (bulkiness of the organic moiety) and the negative
charge for the biological activity (Table S4, ESI†). In 2015,
the same groups synthesized and investigated three further
organoantimony(III)-based POTs, namely the tungstoarsenates
[(PhSbIII){Na(H2O)}As
III
2W19O67(H2O)]
11, [(PhSbIII)2As
III
2W19-
O67(H2O)]
10 and [(PhSbIII)3(B-a-As
IIIW9O33)2]
12.62 These iso-
structural compounds differed in the number of the incor-
porated {PhSbIII} group. The compounds were tested on six
different bacterial strains (three Gram-positive and three Gram-
negative) and exhibited activity against all of them (MIC values
of 7.8–500 mg ml1) (Table S4, ESI†). With increasing number of
attached {PhSbIII} groups the antibacterial activity of the POT
was also enhanced revealing the importance of this organic
group for the biological effectiveness (Fig. 2). This was the first
unambiguous structure–activity relationship for antibacterially
active POMs showing the possibility to fine-tune or synthesize
tailor-made hybrid POMs with enhanced bioactivity. The activity
dependency on the organic moiety {PhSbIII} was later confirmed
when the hybrid compound [(PhSbIII)4(A-a-As
VW9O34)2]
10 was
compared with [(OHSbIII)4(A-a-As
VW9O34)2]
10, which bears
hydroxyl groups in the structure instead of phenyl groups.63
Antibacterial tests revealed that the hybrid POT containing the
organic {PhSbIII} groups was 4–7 times more active than its
inorganic counterpart proving that the organic group is respon-
sible for the improved antibacterial activity (MIC value range of
7.8–62.5 vs. 125–1000 mg ml1).61–63
Another related study was testing the influence of changes
within the organic group of the hybrid POTs on their anti-
bacterial activity.64 For this reason, three organic–inorganic
hybrid structures were synthesized similar to those mentioned
before but with Me2NCH2-derivatized {PhSb
III} groups. These
hybrids were significantly less active than their non-derivatized
counterparts (MIC values of 250–1000 mg ml1). Even slight
changes within the organic {PhSbIII} group had led to dramatic
changes in the bioactivity of the hybrid POT suggesting that
both the number and kind of the organic group is a crucial key
factor for the bioactivity (addition of a Me2HN
+CH2 group to the
{PhSbIII} unit doubles the MIC value). The hybridization
enhanced the stability of the POTs (at physiological conditions)
and their antibacterial activity due to the insertion of hydro-
phobic properties into the POT core, which might assist the
POT in interfering with the peptidoglycan production of the
bacterial cells.
3.2. Quinolone-based antibiotic–POM hybrids
An organic–inorganic antibacterial hybrid complex consisting of
the Keggin POT [HSiW12O40]
3, cobalt (II) cation and the clini-
cally approved antibacterial agent gatifloxacin (C19FH22N3O4),
[CoII(C19FH22N3O4)3][C19FH23N3O4][HSiW12O40] (Fig. 3), showed
activity against Staphylococcus aureus and Escherichia coli
(MIC = 2.52 and 2.42 mg ml1, respectively).65 This unusual
complex was slightly less active than free gatifloxacin against
Escherichia coli when applied at the same mass concentration
(MICHybrid-POT = 2.42 mg ml
1 vs. MICgatifloxacin = 1.28 mg ml
1).
However, when used at the same molar concentration, the
hybrid-complex showed the highest antibacterial activity in this
study indicating synergy between the drug and [HSiW12O40]
3
(MICHybrid-POT = 0.726 mg ml
1). The pristine [HSiW12O40]
3
alone was not active at all.
Another bioactive organic–inorganic hybrid structure
consisting of a POM and a quinolone-based antibiotic is
{[Zn(HPPA)2H2O]2[H2ZnW12O40]} (HPPA = pipemidic acid).
66
This POM–drug hybrid exhibits a quadruple-stranded helical
structure (Fig. 4). Its antibacterial activity against Staphylococcus
aureus and Escherichia coli (judged by the size of the inhibition
zone on agar plates) is similar to those of the sole antibiotic
Fig. 2 Structure–function-relationship of organoantimony(III)-containing POTs. (A) [(PhSbIII)4(A-a-As
VW9O34)2],
10–61 (B) [(PhSbIII)3(B-a-As
IIIW9O33)2]
12,62
(C) [(PhSbIII)2As
III
2W19O67(H2O)]
10 62 and (D) [(PhSbIII){Na(H2O)}As
III
2W19O67(H2O)]
11 62 are illustrated in the polyhedra representation mode, whereas the
organic moiety is shown as sticks. The figure shows that with increasing number of attached (PhSbIII) units the antibacterial activity of the hybrid is increased,
which is indicated by the MIC values in mg ml1 (numbers in small boxes) against Escherichia coli. The red arrow in (B) indicates the location of the third
(PhSbIII) unit as it points toward the background. Color code: tungsten, blue polyhedra; antimony, deep purple; arsenic, magenta; sodium, green (sphere);
carbon, green (sticks) and oxygen, red.
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HPPA and therefore the activity might be attributed to HPPA
due to the lack of unambiguous synergy.
The hybrid compound (C9H8N)3[NbW5O19] showed bio-activity
against Escherichia coli, Salmonella typhimurium (Gram-negative),
Streptococcus agalactiae (Gram-positive) and Lactobacillus acido-
philus (Gram-positive) according to the size of the inhibition
zones of bacterial growth.67 The complex is based on the
Nb-substituted Lindqvist POT [NbW5O19]
3, which is coordi-
nated to three quinolinium cations via hydrogen bonds and
stabilized by p–p stacking interactions (Fig. S1, ESI†). Besides
the quinoline, of which derivatives are known to be antimicro-
bially active, the Nb-substituted POT itself exhibited also good
antibacterial activity but much lower than that of the hybrid
structure. Thus, the synergistic effect of both compounds led to
the high antibacterial activity of the hybrid complex, which was
suggested to be based on the electrostatic/Coulombic inter-
actions between charged ions (e.g. quinolinium cations) and the
charged bacterial cell wall and on the presence of both proton
donor and acceptor groups within the hybrid facilitating the
reactions with the cell membrane and/or bacterial compounds.
4. Antibacterial activity of POM-based
nanocomposites
Hybrid nanocomposites are of great interest for the pharmaco-
logical and medicinal fields as nanocomposite-based drug delivery
systems are very promising for targeted therapies due to the
possibility to deliver therapeutic agents with improved properties
to their destination whileminimizing adverse eﬀects.68,69 Since the
constituents of nanocomposites are usually very diﬀerent in their
structural, physical and chemical properties, their combination
and synergy oﬀers an extraordinary versatility in their function and
bioactivity. The associated nanosize-eﬀect increases the surface of
the reactive and/or bioactive compound and thus enlarges the
interaction area with the target.70 Furthermore, the embedding of
POMs into nanocomposites reduces their toxicity.44 POMs have
been shown to be ideal building blocks for nanocomposites due to
their unique range of properties and their ability to form clusters
of diﬀerent sizes ranging from several angstroms up to the
nanometer scale.
4.1. Chitosan–POM nanocomposites
One well-studied nanocomposite system is that of POM and
chitosan (CT).71 CT is a linear polysaccharide, which results
from the partial N-deacetylation of the biopolymer chitin, and
consists of randomly distributed b-(1-4)-linked D-glucosamine
and N-acetyl-D-glucosamine. In 1992, Draget et al. reported on
the first POM–CT gels, where CT was crosslinked with Mo(VI)
polyoxyanions, however, the exact POMo species was not deter-
mined as the gel was in situ formed by addition of solid MoO3.
72
Later studies revealed that POM-loaded chitosan dramatically
enhances the uptake of POMs into the target cells. For example,
the deposition of [PTi2W10O40]
7 in the human cell lines FaDu
(squamous carcinoma) and HT-29 (colon adenocarcinoma) was
increased by up to 16- and 24-fold (according to the amount of
tungsten in the cell), respectively, via chitosan-loading and the
cytotoxicity was remarkably reduced.73 In 2006, Chen et al.
showed that a CT-Ca3V10O28 complex exhibited strong anti-
bacterial activity against both Gram-negative and -positive
Fig. 3 Structure of [CoII(C19FH22N3O4)3][C19FH23N3O4][HSiW12O40].
65
(A) Structure of the organic–inorganic hybrid is shown, with the POM
[HSiW12O40]
3 being represented as polyhedra and the organic drug as ball
and stick. Color code: tungsten, blue polyhedra; silicon, orange tetrahedron;
cobalt, pink (sphere connecting three gatifloxacinmolecules); carbon, green;
nitrogen, dark blue; fluorine, light blue; oxygen, red. (B) Structural formula of
gatifloxacin is depicted to provide a better understanding of (A).
Fig. 4 Structure of {[Zn(HPPA)2H2O]2[H2ZnW12O40]}.
66 (A) Structure of
the organic–inorganic hybrid is shown, with the POM [H2ZnW12O40]
4
being represented as polyhedra and the organic drug as ball and stick. Color
code: tungsten, blue polyhedra; zinc as a heteroatom, purple tetrahedron;
zinc as a linker, black; carbon, green; nitrogen, dark blue; oxygen, red.
(B) Structural formula of pipemidic acid is depicted to provide a better
understanding of (A). (C) The left- (a) and right- (e) hand helical chains, the
left- (b) and right- (d) double-stranded helical chain and the final quadruple-
stranded helices (c) are shown in both ball and stick and space-filling
representation. (C) Is reprinted from Li et al. (2014)66 with permission from
the copyright holder (Elsevier).
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bacteria (MIC value of 12.5 mg ml1 for both Escherichia coli and
Staphylococcus aureus).49 The CT-Ca3V10O28 exhibited anti-
bacterial activity was comparable to that of the antibiotic
potassium G penicillin (MIC = 12.5 mg ml1) and even higher
than that of ofloxacin (MIC = 25 mg ml1). Both CT and
[V10O28]
6 showed also antibacterial performance on their
own accord which, however, was much lower than that of the
nanocomposite (MICCT = 500 mg ml
1 and MICPOV = 50 mg ml
1)
(Table S4, ESI†). The antibacterial activity of CT is well known
and two mechanisms have been suggested as the cause of their
inhibitory effect:74 (1) CT as a polycation interacts with the
negatively charged bacterial cell wall and in this way electro-
statically disrupts the cell envelope and leads to the leakage of
intracellular substances. (2) Low-molecular-weight CT is able to
penetrate into the cell and inhibits the transcription of RNA
from DNA by directly interacting with DNAmolecules. However,
the mechanism behind the antibacterial activity of both dec-
avanadate [V10O28]
6 and the nanocomposite is not known but
it is considered, as already mentioned earlier (Section 2.2.1), to
be based on the inhibition of ion pumps (e.g. Na+/K+ ATPase).40
Also multilayer films consisting of the Keggin-type structures,
[SiW12O40]
4 and [PMo12O40]
3, and CT have been prepared
and showed antibacterial activity against Escherichia coli.75
Further CT–POM nanocomposites like that between CT and
the redox-active [PMo12O40]
3 (active against Escherichia coli)
confirmed the antibacterial potential of this complex group.
Fiorani et al. tested several nanocomposites derived from low-
molecular weight CTs and different POM-types, namely deca-
vanadate [V10O28]
6, the phosphovanadomolybdic Keggin-structure
[PMo10V2O40]
5 and decatungstate [W10O32]
4, regarding their
antibacterial activity against Escherichia coli and their surface
charge.76 All nanocomposites were antibacterially active in a
dose-dependent manner, whereby systems exhibiting an in total
more positively charge (CT-[PMo10V2O40]
5 and CT-[W10O32]
4)
were more active than less positively charged systems
(CT-[V10O28]
6). This suggests, in this case, a direct correlation
between the activity and the z-potential (surface charge) of the
nanocomposites as those bearing a more positive charge were
able to completely inhibit the bacterial growth (at a concen-
tration of 0.6 mgml1) and induce morphological changes of the
cells. Furthermore, the activity of CT-based complexes depends
on a series of factors like average molecular weight of CT, type of
the crosslinking agent, average nanocomposite size and as
already stated the surface charge of the nanoparticle. Another
CT–POM nanocomposite study explored the difference in the
antibacterial activity between a POT ([PW12O40]
3) and a POMo
([PMo12O40]
3) based spherical nanohybrid capsule.77 In
contrast to the aforementioned CT–POM nanocomposites, where
the POM was added to a pre-processed CT-containing solution,
these structures were synthesized by a micelle-based approach as
the surfactant cetyltrimethylammonium bromide (CTAB) was
used as a cationic nucleating agent leading to CT–CTAB–POM
capsules (Fig. 5). The POMo-containing capsule showed signi-
ficant antibacterial activity against Escherichia coli according to
the resazurin viability assay,78 (cell viability was reduced by
B85% with 50 mg ml1 of the POMo-capsule), whereas the
corresponding POT-containing structure showed no activity.
The reason for this discrepancy was attributed to the different
shape of the nanocomposites as the POMo-based capsules were
more spherical and tended to form capsules of smaller size
(100–200 nm) in comparison to the POT-based systems
(200–300 nm). The smaller size and the more spherical shape
might facilitate the internalization and/or direct contact of the
CT–CTAB–POMo capsules with the bacterial cell (wall).
4.2. POM-based silver and gold nanoparticles
For millennia, ionic silver (Ag+) has been used as a disinfectant
due to its antimicrobial properties. However, it was not until
the turn of the millennium that comprehensive research on the
antibacterial action of silver nanoparticles (AgNPs) was done
revealing their promising activity against a broad range of
microbes with little systemic toxicity towards human and
mammalian cells.79 Silver is believed to electrostatically inter-
act with the bacterial membrane, which results in the destabi-
lization and/or destruction of the cell wall and interference with
the bacterial respiratory chain.80 Therefore, the production of
such AgNPs in conjunction with POMs were considered pro-
mising as both compounds are bioactive and could lead to an
enhanced activity. Indeed, multifunctional films consisting of
[BW12O40]
5 and AgNPs exhibited antibacterial activity against
Escherichia coli as agar plates incubated with the bacterium and
the film did not produce bacterial colonies.81 On the other
hand, the POT alone showed hardly any antibacterial activity
indicating the necessity of the AgNPs within the film. Antibacterial
tests of AgNPs, which were surface-modified by the Keggin-type
POMs H3PW12O40 and H3PMo12O40, showed enhanced physical
damage to both Gram-negative (Escherichia coli) and -positive
(Staphylococcus albus) cells compared to the unmodified
AgNPs.82 At a fixed Ag+ concentration of 1 mM, the AgNPs
caused 36% cell death in Escherichia coli, which increased to
66% and 85% in the case of the AgNPs–H3PW12O40 and the
Ag-NPs–H3PMo12O40 system, respectively, whereas both pristine
POMs did not show antibacterial activity. Similar observations
were made in the case of Staphylococcus albus but to a lesser extent
indicating a lower antibacterial activity against Gram-positive
bacteria (31%, 49% and 57% bacterial cell death, respectively).
Fig. 5 Scheme of the chitosan–cetyltrimethylammonium bromide–POM
capsule.77 POM = [PW12O40]
3 or [PMo12O40]
3, CTAB = cetyltrimethyl-
ammonium bromide and CT = chitosan.
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The antibiotic activity of Ag+ seems to potentiate the action of
the investigated POMs as their synergy led to a remarkable
increase in activity. It is suggested that these POMs are stabi-
lized and transported into the bacterial cells by the AgNPs as
Ag+ is able to disrupt the cell wall under the production of high
concentration of reactive oxygen species (ROS). Furthermore,
the nanoparticles did not exhibit toxicity against human cells
(tested on the human prostate cancer cell line PC3).
The same two POMs, H3PW12O40 and H3PMo12O40, exhibited
similar eﬀects with gold nanoparticles (AuNPs) against Escher-
ichia coli, although AuNPs are normally biocompatible with
this bacterium.83 Surface functionalization of the AuNPs with
POMs turned them into strong antibacterially active agents as
bacterial cell death was increased from 7% to 43% in the case of
H3PW12O40 and to 49% in the case of H3PMo12O40. The anti-
bacterial activity was even further enhanced by modification of
the AuNP–POM systems with cationic lysine leading to cell
death rates of 75% (POT) and 96% (POMo), respectively. In
contrast to the AgNP systems, POMo functionalized AuNPs
showed higher bioactivity than the corresponding POT-
functionalized particles due to a higher contentment of both
gold and lysine in the former system. The significant improve-
ment in activity by lysine modification can be attributed to its
cationic nature, which most likely guides the nanomaterial
towards the negatively charged cell walls and thus increases
the interaction rate between the material and the bacterial cells.
The same experiment against Gram-positive bacteria was not
undertaken as the unmodified AuNPs were already too active on
Staphylococcus albus leading to almost complete bacterial cell
death.83
4.3. Amino acid–/peptide–POM nanocomposites
Compounds having amino acid and/or peptide moieties are
known to possess biological and pharmacological activities,
among them also antibacterial activity.84 Therefore, the asso-
ciation between amino acids/peptides and POMs is a good
strategy to improve their antibacterial properties. Three nano-
rod-amino acid phosphomolybdates, (HGly)3[PMo12O40](Gly)9
(Gly = glycine), (HLys)9[PMo12O40](Lys)4 (Lys = lysine) and
(HHis)3[PMo12O40](His)3 (His = histidine), were reported to have
remarkable antibacterial activity against Escherichia coli as they
produced inhibition zones ofB1.2–1.3 cm on solid growth agar
plates.85 The Keggin POM and the amino acids themselves
had only very weak antibacterial activity (inhibition zone of
B0–0.7 cm) indicating a significant synergy effect, which could
be mainly attributed to the nano-size effect rather than to e.g.
electrostatic aspects as all three compounds were similarly
active independent of the used amino acids. Li et al. demon-
strated the POM-driven ([SiW12O40]
4) self-assembly of short
peptides into multivalent nanofibers (Fig. 6).86 The nanofibers
exhibited high surface areas and concentrated positive charges,
which resulted in antibacterial activity against Escherichia coli
(MIC = 60 mM). The constituents themselves had only poor
activity. The bacterial growth inhibiting effect was suggested to
be based on the electrostatic binding of the cationic peptides
to the cell membrane, on which surface the peptides are
accumulated before they enter the cell in order to induce cell
lysis. However, it cannot be excluded that in this case the role of
the POM was solely the initiation of the self-assembly of the
nanofibers and the subsequent stabilization of the suprastruc-
ture with no direct antibacterial contribution.
4.4. Other POM-based nanocomposites
Nanohybrid membranes consisting of the Keggin POM
H5PV2Mo12O40 and poly(vinylalcohol)/polyethylenimine (PVA/PEI)
exhibited antibacterial activity against the Gram-positive
bacteria Staphylococcus aureus and Bacillus subtilis and the
Gram-negative Escherichia coli and Pseudomonas aeruginosa.87
The bioactivity increased with increasing H5PV2Mo12O40 content
within the PVA/PEI membrane exhibiting MIC values in the range
of 0.02–2 mg ml1 for the Gram-positive and 0.2–2 mg ml1 for
the Gram-negative bacteria (Table S4, ESI†). Another promising
nanocomposite system is that of the same Keggin structure
H5PV2Mo12O40 and bamboo charcoal (BC).
88 BC is a kind of
carbon-based material and one of the most used adsorbents in
extraction studies. The POM–BC system was strongly active
against seven bacterial strains, including both Gram-positive
and -negative strains, in a POMo-concentration dependent
manner (Table S4, ESI†). The nanocomposite with the highest
POMo content (weight ratio of BC : POMo = 1 : 3) exhibited a
MIC of 4 mg ml1 against all tested bacteria. Even antibiotic
resistant strains like the ciprofloxacin-resistant strain of
Pseudomonas aeruginosa (CRPA) were inhibited and at higher
composite concentrations (16 mg ml1 of the most highly POMo-
loaded composite) even completely killed as evidenced by
morphological changes of the respective bacteria. Very recently,
a series of compounds composed of POM and phosphonium
Fig. 6 Structure of the peptide–POM nanocomposite.86 (a) Structure of
the cationic peptides L1–L7, which were used in the study. (b) Ionic self-
assembly of peptide L1 and H4SiW12O40. The figure is reprinted from
Li et al. (2016)86 with permission from the copyright holder (Wiley).
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groups (MePh3P) showed also antibacterial activity against both
Staphylococcus aureus and Escherichia coli, which was even
stronger than that of the antibiotic ampicillin as judged by the
size of the inhibitory zones on agar plates.89 The (MePh3P)n–POM
systems (n = 3 or 4) are based on the Keggin-type POMs
[SiW12O40]
4, [PW12O40]
3 or [PMo12O40]
3 and the quaternary
phosphonium salt methyl triphenyl phosphonium iodide
(MePhPI). It was described that the antibacterial activity increased
with increasing content of crystal water within the structures. This
was attributed to the hydrophilic affinity between the compounds
and the bacterial cell wall as the latter contains hydrophilic
constituents. However, the main factor for the antibacterial activity
of these compounds was the increase of the positive charge of the
phosphonium cations due to the POM-induced polarization,
which increases the electrostatic force between the compounds
and the bacterial cell membrane.
Multilayer films based on the Keggin POMs [SiW12O40]
4
and [PMo12O40]
3 and the dye methylene blue were reported to
be active against Escherichia coli.90 Methylene blue as being
involved in the electron transport of diﬀerent biological pro-
cesses is a natural antibiotic and is used in the photodynamic
therapy of bacteria, fungi, viruses and cancer.91 However, a
control experiment with a PEI-film containing only methylene
blue exhibited negligible activity and therefore the antibacterial
activity of the methylene blue/POMo film could be, at least
partially, ascribed to the Keggin-POMo suggesting some
kind of synergy. A similar study with a layer-by-layer film of
[H4PV6Mo6O40]
5 and methyl violet, which is a strong bacteri-
cide, showed the same result as in the case of methyl blue
as only the POM–dye hybrid film performed antibacterial
activity against Escherichia coli, whereas the control film lacking
POM did not.92
Very recently, the antibacterial potential of POM-ionic
liquids (POM-ILs) were reported.93,94 The studied POM-ILs were
composed of the lacunary Keggin-POT [SiW11O39]
8 (Fig. 1F)
and three antimicrobial tetraalkylammonium cations diﬀering
in their alkyl chain length. All three POM-ILs were active against
the tested bacteria, namely Staphylococcus aureus, Pseudomonas
aeruginosa and Escherichia coli, whereby Staphylococcus aureus
was particularly sensitive to the POM-ILs. The antibacterial
activity of these nanocomposites somehow correlated with the
alkyl chain length of the cations as POM-ILs bearing cations
with C7 and C8 alkyl chains (MIC values of 2–100 mg ml1)
were significantly more active than their counterparts posses-
sing C6 chained cations (MIC values of 10–1000 mg ml1)
(Table S4, ESI†).
The eﬀects of the above described POM-hybrid and nano-
structure on all tested bacteria are summarized in Table 2.
5. Structure–activity-relationship of
antibacterially active POMs and their
putative mechanisms
5.1. Structure–activity-relationship
In total 74 inorganic POMs were tested on the MRSA strains
SR3605 and ATCC43300 (Table S1, ESI†), where only seven
compounds showed considerable antibacterial activity by them-
selves (MIC up to 100 mg ml1). The most eﬀective ones were
double Keggin, Keggin-type and Wells–Dawson-type structures.
Table 2 Overview of the eﬀect of POM-based hybrids and nanocomposites on all tested bacteria
POM-hybrid/nanocomposite Antibacterial active on Ref. POM-hybrid/nanocomposite Antibacterial active on Ref.
Organoantimony-polyoxotungstates: B. subtilis(+) 61–64 PVA/PEI–POM: S. aureus(+) 87
C. michiganensis(+) 62–64 B. subtilis(+) 87
Paenibacillus sp.(+) 62–64 E. coli() 87
E. coli() 61–64 P. aeruginosa() 87
P. putida() 62–64
Vibrio sp.() 62–64 Peptide–POM: E. coli() 85 and 86
Gatifloxacin–POM: S. aureus(+) 65 Bamboo charcoal–POM: S. aureus(+) 88
E. coli() 65 MR S. aureus(+) 88
B. subtilis(+) 88
Zn–pipemidic acid–Zn–POM: S. aureus(+) 66 E. coli() 88
E. coli() 66 P. aeruginosa() 88
CR P. aeruginosa() 88
(C9H8N)3[NbW5O19]: S. agalactiae
(+) 67
L. acidophilus(+) 67 MePh3P–POMs: S. aureus
(+) 89
E. coli() 67 E. coli() 89
S. typhimurium() 67
Chitosan–POMs: S. aureus(+) 49 Multilayer films: E. coli() 90 and 92
E. coli() 49 and 75–77
Ag/AuNPs–POM: S. albus(+) 82 and 83 POM ionic liquids: S. aureus(+) 94
E. coli() 82 and 83 E. coli() 94
P. aeruginosa() 94
(+)/() indicate Gram-positive and -negative bacteria, respectively. MR = methicillin resistant. CR = ciprofloxacin-resistant. For the remaining
bacteria there was either no further information in the respective publication or a normal drug-susceptible bacterium was used. For more
information regarding the exact POM-type, please see Table 3 and Tables S1–S4 (ESI).
Feature Article ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
Ja
nu
ar
y 
20
18
. D
ow
nl
oa
de
d 
on
 2
2/
01
/2
01
8 
18
:1
3:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2018 Chem. Commun.
However, most of the tested POTs exhibited significant anti-
bacterial activity in synergy with b-lactam antibiotics. Analysis of
the structure–activity-relationship considering the parameters
POM size (number of addenda atoms), POM total net charge,
POM charge density (charge per number of addenda atoms),
number of certain atoms within the POM (e.g. different metals
and oxygen atoms) and POM redox potential did neither reveal
any unambiguous correlation nor any trend or structure-
function pattern for these POMs. The same was also observed
for the synergy effect, where no correlation between the POM-
mediated sensitizing effect and its structure was found. How-
ever, considering the biological activity of the so far studied
POMs againstHelicobacter pylori, structure–activity patterns were
identified (Table 3 and Fig. 7). The charge–activity-relationship
of all tested POMs against the IID3023 strain of Helicobacter
pylori was determined (Fig. 7).
From Fig. 7 it can be deduced that POMs possessing a net
charge between 2 to 8 can be divided into two groups,
namely POMs exhibiting MIC values up to 100 mg ml1 (group A)
and those possessing MICs over 200 mg ml1 (group B). Among
POMs belonging to group A, vanadium-containing POMs
showed the highest activity. POMs exhibiting a negative
charge higher than 15 showed the highest activity against
almost all Helicobacter pylori strains (one exception: strain
Hp030, Fig. S4, ESI†) as indicated by MIC values o 50 mg ml1
(group C).
The same or similar trends were observed for 16 of the
17 tested Helicobacter pylori strains (Fig. S2 to S14, ESI†). The
only strain not following this pattern was the clarithromycin-
resistant Hp027, where most of the POMs belonging to group A
(MIC values up to 100 mg ml1 in most of the strains) shifted
towards lower activity and thus to group B (MIC4200 mg ml1)
(Fig. 8). Only the vanadium-containing [SiVW11O40]
8 and the
two large and highly charged POMs from group C maintained
their high activity in this strain. The Wells–Dawson anion
[P2W18O62]
6 was the most strain sensitive POM as depending
on the strain its antibacterial activity was fluctuating the most
(from lower to intermediate activity).
Table 3 Antibacterial activity of POMs alone (MIC) against drug-susceptible and metronidazole- and clarithromycin-resistant H. pylori strains
POM
MIC (mg ml1)
DSSa
Hp Hp Hp IID ATCC Hp Hp
Ref.018b 030b 065b 3023b 43504b 027c 067c
Polyoxotungstate:
Keggin:
H4[SiW12O40] 16–256 128 32 64 32 64 256 64 46
K7[PTi2W10O40] 64–256 256 128 128 64 128 256 64 46
(NH3Pr
i)6H[PTi2W10O38(O2)2] 32–256 64 64 32 32 64 256 64 46
Wells–Dawson:
K6[P2W18O62] 256 to 4256 128 n.d.
d 256 256 256 256 256 46
Decatungstate:
Na9[EuW10O36] 4256 4256 n.d.
d 4256 4256 4256 4256 4256 46
Other structure:
K27[KAs4W40O140] 16 16 16 16 8 8 8 32 46
K18[KSb9W21O86] 16–64 16 64 16 8 16 8 32 46
Polyoxovanadotungstate:
Keggin:
K5[PV
IVW11O40] 16–256 32 64 128 64 32 256 128 46
K5[SiV
VW11O40] 16–256 64 16 16 16 64 64 64 46
K7[BV
IVW11O40] 32–256 32 16 128 16 32 128 64 46
Polyoxomolybdate:
Keggin:
H3[PMo12O40] 4256 4256 n.d.
d 4256 4256 4256 4256 4256 46
Anderson-Evans:
Na3[CrMo6O24H6] 4256 4256 4256 4256 4256 4256 4256 4256 46
Heptamolybdate:
(NH4)6[Mo7O24] 4256 4256 4256 4256 4256 4256 4256 4256 46
Antibiotic:
Amoxicillin 0.001–0.063 0.008 0.032 0.063 0.016 0.032 2 0.25 46
Clarithromycin 0.001–0.125 0.032 0.004 16 0.032 0.032 32 256 46
Metronidazole 0.5–4 32 16 128 128 128 4 2 46
a Ten drug-susceptible strains (DSS) of H. pylori were tested and the MIC range is given. No further information about the exact strains is given.
b Hp018, Hp030, Hp065, IID3023 and ATCC43504 are metronidazole (MTZ)-resistant H. pylori strains. c Hp027 and Hp067 are clarithromycin
(CLR)-resistant H. pylori strains. d No data available. NH3Pr
i = isopropylammonium.
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Regarding the POM size vs. activity correlation, where the
size is defined as the total number of addenda atoms, a similar
pattern as described above for the charge was observed (Fig. 9).
Thus, POMs exhibiting a size from 6 to 22 addenda atoms can
also be subdivided into group A (MIC up to 100 mg ml1) and
group B (MIC 4 200 mg ml1), whereas the huge and highly
charged [KSb9W21O86]
18 and [KAs4W40O140]
27 form again
their own group C (MIC o 50 mg ml1). Within both the
charge–activity- and size–activity-relationship, there are some
POMs showing intermediate activities (MIC value between 100
and 200 mg ml1), for example, [BVW11O40]
7 against the strain
Hp027 (Fig. 8). According to the above observations, Helicobacter
pylori is most sensitive to large and highly negatively charged
POMs but also susceptible to Keggin-type POMs with vanadium-
substituted structures being among the most effective ones.
On the other hand, the least active POMs were in general
POMos and POMs with other than Keggin-type structures like
the Anderson-Evans and decatungstate structure (Fig. 8 and
Fig. S2–S14, ESI†).
The same structure–activity analysis was performed for
Streptococcus pneumoniae revealing that this bacterium is
especially sensitive to POVs with decavanadate exhibiting the
highest antibacterial activity (Fig. 10 and 11). In contrast to
Helicobacter pylori, most of the tested POMos were determined
to be more active than POTs (Table S3, ESI†). Furthermore,
as can be seen in Fig. 10 and 11, isostructural POMs (Keggin-
type) present completely different antibacterial activity with
MIC values ranging from 192 mg ml1 for [HMo9V3O38]
6 to
6000 mg ml1 for [PTi2W10O40]
7 indicating the generally low
response of this bacterium towards this POM-type. According to
our analysis, the activity of POMs are highly bacteria-dependent
as different bacteria react distinctly to certain types of metal
species and it seems that there is a certain threshold for the
parameters charge, size and shape (POM-type) determining the
biological activity of POMs. However, decavanadate seems to be
special in this regard as it exhibits promising antibacterial
activity against the majority of the tested bacteria, which most
likely is connected to its putative mechanisms of action as
its biological behavior and activity is well studied not only
in vitro but also in vivo.38,40,95–101 However, the susceptibility of
certain bacterial strains (e.g. Streptococcus pneumoniae) towards
vanadium-containing POMs could be also indicative of the
Fig. 7 Charge–activity-relationship of POMs against the metronidazole-
resistant strain IID3023 of Helicobacter pylori. The net charges of the
POMs are plotted against their MIC values. Specific groups are marked,
namely group A (red) of POMs with higher activity (MIC up to 100 mg ml1),
group B (blue) of POMs with lower activity (MIC4 200 mg ml1) and group
C (green) of large and highly charged POMs exhibiting the highest activity.
CrMo6 = [CrMo6O24H6]
3, PMo12 = [PMo12O40]
3, Mo7 = [Mo7O24]
6,
EuW10 = [EuW10O36]
9, P2W18 = [P2W18O62]
6, PVW11 = [PVW11O40]
5,
PTi2W10 = [PTi2W10O40]
7, W10(O2)2 = [PTi2W10O38(O2)2]
7, SiW12 =
[SiW12O40]
4, SiVW11 = [SiVW11O40]
7, BVW11 = [BVW11O40]
7, Sb9W21 =
[KSb9W21O86]
18, As4W40 = [KAs4W40O140]
27.
Fig. 8 Charge–activity-relationship of POMs against the clarithromycin-
resistant strain Hp027 of Helicobacter pylori. The net charges of the POMs
are plotted against their MIC values. Specific groups are marked, namely
group A (red) of POMs with higher activity (MIC up to 100 mg ml1), group B
(blue) of POMs with lower activity (MIC 4 200 mg ml1) and group C
(green) of large and highly charged POMs exhibiting the highest activity.
Between MIC values of 100 and 200 mg ml1 there is an intermediate zone
(black) representing moderately active POMs. For full POM formula, see
caption of Fig. 7.
Fig. 9 Size–activity-relationship of POMs against the metronidazole-
resistant strain IID3023 of Helciobacter pylori. Specific groups are marked,
namely group A (red) of POMs with higher activity (MIC up to 100 mg ml1),
group B (blue) of POMs with lower activity (MIC4 200 mg ml1) and group
C (green) of large and highly charged POMs exhibiting the highest activity.
For full POM formula, see caption of Fig. 7.
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involvement of redox-processes in the killing process as vana-
dium is most readily reduced, among the typical addenda atoms
(W, Mo and V), leading to an increase in the redox activity of the
corresponding POMs.102 Another function-activity-relationship
was already mentioned in Section 3.1, where a series of
organoantimony(III)-containing POTs showed a direct correlation
between their antibacterial activity and the amount of attached
organic moieties.
Note, that it is in general diﬃcult to deduce structure–
activity correlations for POMs as their stability is a critical issue
and therefore the identity of the active species is unknown for
most POMs, especially in cases, where the POMs have been
analyzed in bacterial growth media. In addition to this, the
available data describing the antibacterial activity of POMs is
more or less biased as the vast majority of the tested com-
pounds are Keggin-based structures leading to a clustering of
data in favor of this archetype.
5.2. Putative mode of actions
The putative mechanisms of action of POMs with antibacterial
activity can be briefly resumed in the scheme of Fig. 12.
The POM targets include extracellular- and membrane-associated
proteins/enzymes and processes such as respiration96 (or other
redox processes) or cytoskeleton dynamics.39,56 POMs were
successfully localized within or at the inner membrane of
bacteria, suggesting the interference or interaction with the
bacterial cell wall and membrane compounds (Fig. 12, A).46,48
There is no report about antibacterial POMs reaching the
cytoplasm, however, some suggested mechanisms would highly
benefit from POMs being active within the cytoplasmic space.
There are some theories suggesting that POMs (without con-
sidering hybrid or nanocomposite structures) could be inter-
nalized by some surface proteins via endocytosis-like processes,
for example, macrophage receptors as it was proposed that
POTs do compete with their ligand, acetylated low density
lipoprotein, for receptor binding.103 Depending on the POM
type, the transcription or translation or even both processes of
PBP2a are reduced.27 In addition, POMs inhibit the production
of b-lactamases.43 Thus, POMs are able to interfere with two
proteins that are responsible for the b-lactam resistance of
some bacteria (Fig. 12, B). However, the exact mode of action
is unknown but POMs might interact with protein targets,
which are part of a signal cascade necessary for the production
of the aforementioned proteins. POMs, especially decavanadate,
were shown to be potent inhibitors of P-type ATPases and thus it
is suggested that, at least partially, the malfunction of ATPases
is also responsible for the observed antibacterial eﬀects.40
Fig. 10 Size–activity-relationship of POMs against six strains of Strepto-
coccus pneumoniae. (A) The sizes of the POMs expressed as number of
addenda atoms are plotted against their MIC values. (B) Zoom view of
(A) by plotting the MIC value only in the range of 0 to 25 mg ml1. PMo12 =
[PMo12O40]
3, Mo6V2 = [Mo6V2O26]
6, HMo9V3 = [HMo9V3O38]
6, Mo7 =
[Mo7O24]
6, Mo8 = [Mo8O26]
4, EuW10 = [EuW10O36]
9, PVW11 = [PVW11O40]
5,
PTi2W10 = [PTi2W10O40]
7, PW12 = [PW12O40]
3, [BVW11]
6 = [BVVW11O40]
6,
[BVW11]
7 = [BVIVW11O40]
7, PV3W9 = [PV3W9O40]
6, Sb9W21 =
[KSb9W21O86]
18, V4 = [V4O12]
4, VW5 = [VW5O19]
4, V10 = [V10O28]
6,
MnV13 = [MnV13O38]
7, NiV13 = [NiV13O38]
7, V15 = [V15O36(CO3)]
7, V18 =
[V18O42(H2O)]
12.
Fig. 11 Charge–activity-relationship of POMs against six strains of Strepto-
coccus pneumoniae. (A) The sizes of the POMs expressed as number of
addenda atoms are plotted against their MIC values. (B) Zoom view of (A) by
plotting the MIC value only in the range of 0 to 25 mg ml1. For POM sum
formula, see caption of Fig. 10.
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Inhibition of P-type ATPases has a severe impact on the cellular
metabolism (Fig. 12, C). As most POMs are highly redox-active,
they could impair the bacterial electron-transport-chain (respira-
tory system) by oxidizing important electron carriers like NADH
and thus aﬀect ATP production.98,104 This in turn leads to lethal
damage in bacterial cells (Fig. 12, D). One aftermath of impairing
the respiratory system is the increase of the ROS level. However,
POMs can also directly produce ROS by oxidizing proteins, lipids
and other bacterial compounds (Fig. 12, E). In addition, POMs are
able to elevate the ROS level by oxidizing the antioxidant gluta-
thione (GSH), which leads to the depletion of the GSH-pool.105
POMs can also react with important membrane anchored pro-
teins and enzymes, which could lead to serious damage within the
bacterial cell. For example, some POMs are able to inhibit sialyl-
and sulfotransferases and thus could interfere with the bacterial
carbohydrate metabolism (Fig. 12, F).106 Another possible
mechanism is the disruption of the bacterial cytoskeleton
dynamics by POM-interactions with cytoskeletal elements like
FtsZ and MreB (Fig. 12, Q). Some POM-based nanocomposites
like CT–POMs or AgNP–POMs are able to disrupt the bacterial
cell wall, which leads to the leakage of intracellular substances
(Fig. 12, 8a).74,79 Once the cell wall is disrupted, POMs could
interact with cytoplasmic elements or proteins that are anion-
sensitive like nucleic acid binding proteins. On the other hand,
other constituents of the hybrid system like CT can directly
interact with DNA molecules and thus causing lethal damages
to the bacteria (Fig. 12, 8b).74
In general, it seems that POM–protein interactions are mainly
responsible for the antibacterial activity of the inorganic compounds.
As these interactions are of electrostatic nature, almost every protein
is a potential target for POMs as they normally bear positively
charged regions. Besides the (possibly) reversible electrostatic inter-
actions, POMs are also able to covalently bind to proteins.6,35 This
demonstrates the wide applicability of POMs in biological fields. Due
to the POM’s ability to inhibit a series of biologically relevant
proteins and enzymes, the mode of action of antibacterially active
POMs might not be explained by one strict mechanism with one
single target but rather by multiple POM–protein interactions affect-
ing several biological pathways at the same time and the sum of
these disturbances ultimately leads to the death of the bacterial cell.6
In the next years, we expect that important questions will be
answered: (1) What is the exact mechanism of POM uptake? (2)
Where is the exact location of the POM and (3) its action within
the cell? (4) What is the exact bioactive POM species and how
does it function (mode of action)? (5) What is the exact mecha-
nism of POM-induced bacterial resistance reversion? These and
other questions will require continuous development of new
techniques and approaches to explore the eﬀects of POMs on
bacteria and their medicinal applications in more detail.
6. Conclusions and future perspective
The high potential of POMs, especially POM-based hybrid systems,
as antibacterial agents has been proved by the research activities
Fig. 12 Schematic overview of the putative mechanisms of antibacterially active POMs. A POMs are uptaken into the inner membrane but not into the
cytoplasm. B POMs inhibit the production of both PBP2a (green squares) and b-lactamases (green circles). C POMs, especially decavanadate, target
P-type ATPases. D Impairment of the bacterial electron-transport-chain (respiratory system) by POMs. E POM-mediated increase of the ROS-level via
oxidation. F POMs can also react with important membrane anchored proteins and enzymes (red triangle and purple pentagon). Q The disruption of the
bacterial cytoskeleton dynamics by POM-interactions with cytoskeletal elements (yellow triangles). (8a) POM-based nanocomposites (e.g. CT–POMs or
AgNP–POMs) are able to disrupt the bacterial cell wall leading to leakage of intracellular substances (blue and red circles). (8b) Upon cell wall disruption,
POMs could interact with cytoplasmic elements or proteins that are anion-sensitive like nucleic acid binding proteins.
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of the last two decades. POMs have been shown to be active on
both Gram-negative and Gram-positive bacteria, among them
also highly hazardous antibiotic resistant bacterial strains, and
were partially more active than commonly used antibiotics.
POMs were shown to exhibit great synergy with some conven-
tional antibiotic agents, which is especially important for the
treatment of highly resistant bacteria, but also direct anti-
bacterial activity was observed. An analysis of the structure–
activity-relationship of a series of POMs against two bacteria,
namely Helicobacter pylori and Streptococcus pneumoniae, indi-
cated that isostructural POMs, despite having the same size
and similar charge, can be split into two groups according to
their activity. Regarding Helicobacter pylori, POMs exhibiting
the highest activity were mostly Keggin-type POTs, polyoxo-
vanadotungstates and large highly negatively charged POMs,
whereas in the case of Streptococcus pneumoniae, the most
active POMs were ascribed to be POVs, especially decavanadate,
which was also very active against other bacteria. Despite the
considerable potential of POMs as metallodrugs, applications
of inorganic POMs in medicinal fields are prevented by both
their toxicity and the lack of knowledge about their mode of
action. The former issue can be avoided by formation of hybrid
structures, which were shown to drastically reduce the toxicity
arising from the pristine POM. Nevertheless, more studies are
needed to explore the biological effects of POMs that causes
their toxicity. Furthermore, comprehensive investigations on
more bacteria using more quantitative methods have to be
performed to better decipher the structure–activity-relationship
of bioactive POMs. For this reason, it would be beneficial to
establish a standard method to normalize the evaluation of
POM-mediated antibacterial activity. It also requires the step
up of the research effort to tackle the problem regarding the
mode of antibacterial action of POMs as both bacterial growth
inhibition and cell death are associated with a great cascade of
reactions making it enormously challenging to pinpoint the
exact inhibitory event. Therefore, interdisciplinary collabora-
tions are needed to collect and accumulate contributions from
different research fields like inorganic chemistry (POM chem-
istry), pharmacy/medicinal chemistry (antibacterial effect of
POMs), crystallography (structure of POM-target complexes)
and biochemistry (location of POM action). Future research
will be focused on the development of novel hybrid compounds
with enhanced stability and biological activity and reduced
toxicity. Besides investigating more bacteria strains, the detec-
tion of potential target enzymes and the analysis of their
interaction with POMs will be at the top of the agenda of future
research. As POMs were only found to be located at the periphery
of bacterial cells, the search for potential targets should be
shifted towards extracellular or membrane-associated proteins,
which are accessible without the need of POM penetration into
the cytoplasm. Furthermore, from a medical point of view,
membrane proteins represent the most important group of
proteins/enzymes as their functions are vital for the survival of
organisms. In this way, structure–activity relationships can be
elaborated enabling the targeted synthesis of powerful POM-
based antibiotic compounds.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
The research was funded by the Austrian Science Fund (FWF):
P27534. MA thanks the national funds through FCT, Foundation
for Science and Technology (UID/Multi/04326/2013; SFRH/BSAB/
129821/2017).
Notes and references
1 M. T. Pope, Heteropoly and isopoly oxometalates, Springer-Verlag,
Berlin, New York, 1983.
2 S.-S. Wang and G.-Y. Yang, Chem. Rev., 2015, 115, 4893–4962.
3 E. Papaconstantinou and A. Hiskia, Polyoxometalate Molecular
Science, Springer, Dordrecht, 2003, pp. 381–416.
4 B. Viswanathan, Environmentally Benign Catalysts, Springer,
Dordrecht, 2013, pp. 245–255.
5 N. Casan˜-Pastor and P. Go´mez-Romero, Front. Biosci., 2004, 9,
1759–1770.
6 A. Bijelic and A. Rompel, Coord. Chem. Rev., 2015, 299, 22–38.
7 A. Bijelic and A. Rompel, Acc. Chem. Res., 2017, 50, 1441–1448.
8 J. T. Rhule, C. L. Hill, D. A. Judd and R. F. Schinazi, Chem. Rev.,
1998, 98, 327–358.
9 M. Arefian, M. Mirzaei, H. Eshtiagh-Hosseini and A. Frontera,
Dalton Trans., 2017, 46, 6812–6829.
10 A. Proust, B. Matt, R. Villanneau, G. Guillemot, P. Gouzerh and
G. Izzet, Chem. Soc. Rev., 2012, 41, 7605–7622.
11 A. Blazevic, E. Al-Sayed, A. Roller, G. Giester and A. Rompel, Chem.
– Eur. J., 2015, 21, 4762–4771.
12 E. Al-Sayed, A. Blazevic, A. Roller and A. Rompel, Chem. – Eur. J.,
2015, 21, 17800–17807.
13 A. Blazevic and A. Rompel, Coord. Chem. Rev., 2016, 307, 42–64.
14 N. I. Gumerova, A. Roller and A. Rompel, Eur. J. Inorg. Chem., 2016,
5507–5511.
15 N. I. Gumerova, A. Roller and A. Rompel, Chem. Commun., 2016, 52,
9263–9266.
16 G. Izzet, F. Volatron and A. Proust, Chem. Rec., 2017, 17, 250–266.
17 N. I. Gumerova, L. Krivosudsky´, G. Fraqueza, J. Breibeck, E. Al-Sayed,
E. Tanuhadi, A. Bijelic, J. Fuentes, M. Aureliano and A. Rompel,
Metallomics, 2018, DOI: 10.1039/c7mt00279c.
18 J. C. Chermann, M. Raynaud, C. Jasmin and G. Mathe´, Nature,
1970, 227, 173–174.
19 Y. Inouye, Y. Tokutake, J. Kunihara, T. Yoshida, T. Yamase,
A. Nakata and S. Nakamura, Chem. Pharm. Bull., 1992, 40, 805–807.
20 M. Witvrouw, H. Weigold, C. Pannecouque, D. Schols, E. De Clercq
and G. Holan, J. Med. Chem., 2000, 43, 778–783.
21 D. A. Judd, J. H. Nettles, N. Nevins, J. P. Snyder, D. C. Liotta,
J. Tang, J. Ermolieﬀ, R. F. Schinazi and C. L. Hill, J. Am. Chem. Soc.,
2001, 123, 886–897.
22 K. Nomiya, H. Torii, T. Hasegawa, Y. Nemoto, K. Nomura,
K. Hashino, M. Uchida, Y. Kato, K. Shimizu and M. Oda, J. Inorg.
Biochem., 2001, 86, 657–667.
23 B. Hasenknopf, Front. Biosci., 2005, 10, 275–287.
24 Z. Ilyas, H. Saeed Shah, R. Al-Oweini, U. Kortz and J. Iqbal,
Metallomics, 2014, 6, 1521–1526.
25 S. Trevin˜o, D. Vela´zquez-Va´zquez, E. Sa´nchez-Lara, A. Diaz-
Fonseca, J. A´. Flores-Hernandez, A. Pe´rez-Benı´tez, E. Brambila-
Colombres and E. Gonza´lez-Vergara, Oxid. Med. Cell. Longevity,
2016, 6058705.
26 T. Yamase, H. Fujita and K. Fukushima, Inorg. Chim. Acta, 1988,
151, 15–18.
27 T. Yamase, J. Mater. Chem., 2005, 15, 4773–4782.
28 Y. Tajima, Z. Nagasawa and J. Tadano, Microbiol. Immunol., 1993,
37, 695–703.
29 T. L. Turner, V. H. Nguyen, C. C. McLauchlan, Z. Dymon, B. M.
Dorsey, J. D. Hooker and M. A. Jones, J. Inorg. Biochem., 2012, 108,
96–104.
ChemComm Feature Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
Ja
nu
ar
y 
20
18
. D
ow
nl
oa
de
d 
on
 2
2/
01
/2
01
8 
18
:1
3:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Chem. Commun. This journal is©The Royal Society of Chemistry 2018
30 S. G. Mauracher, C. Molitor, R. Al-Oweini, U. Kortz and A. Rompel,
Acta Crystallogr., Sect. F: Struct. Biol. Commun., 2014, 70,
263–266.
31 S. G. Mauracher, C. Molitor, R. Al-Oweini, U. Kortz and A. Rompel,
Acta Crystallogr., Sect. D: Biol. Crystallogr., 2014, 70, 2301–2315.
32 A. Bijelic, C. Molitor, S. G. Mauracher, R. Al-Oweini, U. Kortz and
A. Rompel, ChemBioChem, 2015, 16, 233–241.
33 C. Molitor, S. G. Mauracher and A. Rompel, Acta Crystallogr., Sect.
F: Struct. Biol. Commun., 2015, 71, 746–751.
34 C. Molitor, S. G. Mauracher and A. Rompel, Proc. Natl. Acad. Sci.
U. S. A., 2016, 113, E1806–1815.
35 C. Molitor, A. Bijelic and A. Rompel, Chem. Commun., 2016, 52,
12286–12289.
36 C. Molitor, A. Bijelic and A. Rompel, IUCrJ, 2017, 4, 734–740.
37 H. Stephan, M. Kubeil, F. Emmerling and C. E. Mu¨ller, Eur. J. Inorg.
Chem., 2013, 1585–1594.
38 G. Borges, P. Mendonça, N. Joaquim, J. Coucelo and M. Aureliano,
Arch. Environ. Contam. Toxicol., 2003, 45, 415–422.
39 S. Ramos, J. J. G. Moura and M. Aureliano, J. Inorg. Biochem., 2010,
104, 1234–1239.
40 M. Aureliano, G. Fraqueza and C. A. Ohlin, Dalton Trans., 2013, 42,
11770–11777.
41 Y. Tajima, J. Inorg. Biochem., 1997, 68, 93–99.
42 T. Yamase, N. Fukuda and Y. Tajima, Biol. Pharm. Bull., 1996, 19,
459–465.
43 N. Fukuda, T. Yamase and Y. Tajima, Biol. Pharm. Bull., 1999, 22,
463–470.
44 Y. Tajima, Biol. Pharm. Bull., 2001, 24, 1079–1084.
45 Y. Tajima, Biomed. Res., 2002, 23, 115–125.
46 M. Inoue, K. Segawa, S. Matsunaga, N. Matsumoto, M. Oda and
T. Yamase, J. Inorg. Biochem., 2005, 99, 1023–1031.
47 N. H. Georgopapadakou, Antimicrob. Agents Chemother., 1993, 37,
2045–2053.
48 M. Inoue, T. Suzuki, Y. Fujita, M. Oda, N. Matsumoto and T. Yamase,
J. Inorg. Biochem., 2006, 100, 1225–1233.
49 S. Chen, G. Wu, D. Long and Y. Liu, Carbohydr. Polym., 2006, 64,
92–97.
50 N. Fukuda and T. Yamase, Biol. Pharm. Bull., 1997, 20, 927–930.
51 M. Aureliano and V. M. Madeira, Biochem. Biophys. Res. Commun.,
1994, 205, 161–167.
52 L. Yatime, M. J. Buch-Pedersen, M. Musgaard, J. P. Morth, A.-M. L.
Winther, B. P. Pedersen, C. Olesen, J. P. Andersen, B. Vilsen,
B. Schiøtt, M. G. Palmgren, J. V. Møller, P. Nissen and N. Fedosova,
Biochim. Biophys. Acta, Bioenerg., 2009, 1787, 207–220.
53 B. Rouzaire-Dubois and J. M. Dubois, Toxicon, 1990, 28,
1147–1158.
54 M. Pelin, S. Boscolo, M. Poli, S. Sosa, A. Tubaro and C. Florio, Mar.
Drugs, 2013, 11, 584–598.
55 M. T. Cabeen and C. Jacobs-Wagner, Nat. Rev. Microbiol., 2005, 3,
601–610.
56 M. P. M. Marques, D. Gianolio, S. Ramos, L. A. E. Batista de Carvalho
and M. Aureliano, Inorg. Chem., 2017, 56, 10893–10903.
57 H. P. Erickson, Nature, 2001, 413, 30.
58 J. W. Shaevitz and Z. Gitai, Cold Spring Harbor Perspect. Biol., 2010,
9, a000364, DOI: 10.1101/cshperspect.a000364.
59 E. Bae, J. W. Lee, B. H. Hwang, J. Yeo, J. Yoon, H. J. Cha and
W. Choi, Chemosphere, 2008, 72, 174–181.
60 Y. Tajima, Z. Nagasawa, I. Tanabe, K. Kusaba and J. Tadano,
Microbiol. Immunol., 1994, 38, 639–648.
61 M. Barsukova-Stuckart, L. F. Piedra-Garza, B. Gautam, G. Alfaro-
Espinoza, N. V. Izarova, A. Banerjee, B. S. Bassil, M. S. Ullrich,
H. J. Breunig, C. Silvestru and U. Kortz, Inorg. Chem., 2012, 51,
12015–12022.
62 P. Yang, B. S. Bassil, Z. Lin, A. Haider, G. Alfaro-Espinoza,
M. S. Ullrich, C. Silvestru and U. Kortz, Chem. – Eur. J., 2015, 21,
15600–15606.
63 P. Yang, Z. Lin, B. S. Bassil, G. Alfaro-Espinoza, M. S. Ullrich, M.-X.
Li, C. Silvestru and U. Kortz, Inorg. Chem., 2016, 55, 3718–3720.
64 P. Yang, Z. Lin, G. Alfaro-Espinoza, M. S. Ullrich, C. I. Rat-,
C. Silvestru and U. Kortz, Inorg. Chem., 2016, 55, 251–258.
65 H. Liu, Y.-L. Zou, L. Zhang, J.-X. Liu, C.-Y. Song, D.-F. Chai, G.-G.
Gao and Y.-F. Qiu, J. Coord. Chem., 2014, 67, 2257–2270.
66 L. Li, J.-Q. Sha, X.-M. Zong, C.-J. Liu, Q.-N. Zhang, D.-W. Wang,
X.-N. Yang and Y. Wang, J. Mol. Struct., 2014, 1064, 94–99.
67 A. Maalaoui, A. Hajsalem, N. Ratel-Ramond and S. Akriche,
J. Cluster Sci., 2014, 25, 1525–1539.
68 W. H. De Jong and P. J. Borm, Int. J. Nanomed., 2008, 3,
133–149.
69 D. Feldman, J. Macromol. Sci., Part A: Pure Appl. Chem., 2016, 53,
55–62.
70 F. Watari, N. Takashi, A. Yokoyama, M. Uo, T. Akasaka, Y. Sato,
S. Abe, Y. Totsuka and K. Tohji, J. R. Soc., Interface, 2009, 6,
S371–S388.
71 H. S. Shah, R. Al-Oweini, A. Haider, U. Kortz and J. Iqbal, Toxicol.
Rep., 2014, 1, 341–352.
72 K. I. Draget, K. M. Va¨rum, E. Moen, H. Gynnild and O. Smidsrød,
Biomaterials, 1992, 13, 635–638.
73 T. Meißner, R. Bergmann, J. Oswald, K. Rode, H. Stephan,
W. Richter, H. Za¨nker, W. Kraus, F. Emmerling and G. Reck,
Transition Met. Chem., 2006, 31, 603–610.
74 R. C. Goy, D. de Britto and O. B. G. Assis, Polimeros, 2009, 19,
241–247.
75 Y. Feng, Z. Han, J. Peng, J. Lu, B. Xue, L. Li, H. Ma and E. Wang,
Mater. Lett., 2006, 60, 1588–1593.
76 G. Fiorani, O. Saoncella, P. Kaner, S. A. Altinkaya, A. Figoli,
M. Bonchio and M. Carraro, J. Cluster Sci., 2014, 25, 839–854.
77 L. De Matteis, S. G. Mitchell and J. M. de la Fuente, J. Mater. Chem.
B, 2014, 2, 7114–7117.
78 T. L. Riss, R. A. Moravec, A. L. Niles, S. Duellman, H. A. Benink,
T. J. Worzella and L. Minor, in Assay Guidance Manual, ed.
G. S. Sittampalam, N. P. Coussens, K. Brimacombe, A. Grossman,
M. Arkin, D. Auld, C. Austin, J. Baell, B. Bejcek, T. D. Y. Chung,
J. L. Dahlin, V. Devanaryan, T. L. Foley, M. Glicksman, M. D. Hall,
J. V. Hass, J. Inglese, P. W. Iversen, S. D. Kahl, S. C. Kales,
M. Lal-Nag, Z. Li, J. McGee, O. McManus, T. Riss, O. J. Trask,
J. R. Weidner, M. Xia and X. Xu, Eli Lilly & Company and the
National Center for Advancing Translational Sciences, Bethesda
(MD), 2004.
79 B. Le Ouay and F. Stellacci, Nano Today, 2015, 10, 339–354.
80 W. K. Jung, H. C. Koo, K. W. Kim, S. Shin, S. H. Kim and Y. H. Park,
Appl. Environ. Microbiol., 2008, 74, 2171–2178.
81 S. Gao, Z. Wu, D. Pan, Z. Lin and R. Cao, Thin Solid Films, 2011,
519, 2317–2322.
82 H. K. Daima, P. R. Selvakannan, A. E. Kandjani, R. Shukla,
S. K. Bhargava and V. Bansal, Nanoscale, 2014, 6, 758–765.
83 H. K. Daima, P. R. Selvakannan, R. Shukla, S. K. Bhargava and
V. Bansal, PLoS One, 2013, 8, e79676.
84 H. Jenssen, P. Hamill and R. E. W. Hancock, Clin. Microbiol. Rev.,
2006, 19, 491–511.
85 Y. Kong, L. Pan, J. Peng, B. Xue, J. Lu and B. Dong, Mater. Lett.,
2007, 61, 2393–2397.
86 J. Li, Z. Chen, M. Zhou, J. Jing, W. Li, Y. Wang, L. Wu, L. Wang,
Y. Wang and M. Lee, Angew. Chem., Int. Ed., 2016, 55, 2592–2595.
87 K. H. Wu, P. Y. Yu, C. C. Yang, G. P. Wang and C. M. Chao, Polym.
Degrad. Stab., 2009, 94, 1411–1418.
88 F.-C. Yang, K.-H. Wu, W.-P. Lin and M.-K. Hu,Microporous Mesoporous
Mater., 2009, 118, 467–472.
89 S. Hu, C. Ma, F. Zhan, Y. Cao, P. Hu and Q. Zhen, Chem. Pap., 2017,
71, 1323–1329.
90 D. Chen, J. Peng, H. Pang, P. Zhang, Y. Chen, C. Chen and H. Ma,
Z. Naturforsch., 2014, 65, 140–146.
91 P. R. Ginimuge and S. D. Jyothi, J. Anaesthesiol., Clin. Pharmacol.,
2010, 26, 517–520.
92 X. Yu, C. Chen, J. Peng, Z. Shi, Y. Shen, J. Mei and Z. Ren, Thin Solid
Films, 2014, 571, 69–74.
93 S. Herrmann, L. De Matteis, J. M. de la Fuente, S. G. Mitchell and
C. Streb, Angew. Chem., Int. Ed., 2017, 56, 1667–1670.
94 A.-L. Kubo, L. Kremer, S. Herrmann, S. G. Mitchell, O. M.
Bondarenko, A. Kahru and C. Streb, ChemPlusChem, 2017, 82,
867–871.
95 M. Aureliano and C. A. Ohlin, J. Inorg. Biochem., 2014, 137,
123–130.
96 M. Aureliano, Oxid. Med. Cell. Longevity, 2016, 2016, 6103457.
97 R. M. C. Gaˆndara, S. S. Soares, H. Martins, C. Gutie´rrez-Merino and
M. Aureliano, J. Inorg. Biochem., 2005, 99, 1238–1244.
98 S. S. Soares, H. Martins, R. O. Duarte, J. J. G. Moura, J. Coucelo,
C. Gutie´rrez-Merino and M. Aureliano, J. Inorg. Biochem., 2007, 101,
80–88.
Feature Article ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
Ja
nu
ar
y 
20
18
. D
ow
nl
oa
de
d 
on
 2
2/
01
/2
01
8 
18
:1
3:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2018 Chem. Commun.
99 D. M. Tiago, V. Laize´, M. L. Cancela and M. Aureliano, Cell Biol.
Toxicol., 2008, 24, 253–263.
100 S. S. Soares, H. Martins, C. Gutie´rrez-Merino andM. Aureliano, Comp.
Biochem. Physiol., Part C: Toxicol. Pharmacol., 2008, 147, 168–178.
101 S. S. Soares, C. Gutie´rrez-Merino and M. Aureliano, J. Inorg. Biochem.,
2007, 101, 789–796.
102 X. Lo´pez, C. Bo and J. M. Poblet, J. Am. Chem. Soc., 2002, 124,
12574–12582.
103 L. Ni, P. Greenspan, R. Gutman, C. Kelloes, M. A. Farmer and
F. D. Boudinot, Antiviral Res., 1996, 32, 141–148.
104 B. Keita, K. Essaadi, L. Nadjo and M. Desmadril, Chem. Phys. Lett.,
1995, 237, 411–418.
105 P. Sami, T. D. Anand, M. Premanathan and K. Rajasekaran,
Transition Met. Chem., 2010, 35, 1019–1025.
106 A. Seko, T. Yamase and K. Yamashita, J. Inorg. Biochem., 2009, 103,
1061–1066.
ChemComm Feature Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
Ja
nu
ar
y 
20
18
. D
ow
nl
oa
de
d 
on
 2
2/
01
/2
01
8 
18
:1
3:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
